Paul Hjemdahl

List of Publications by Year
in descending order

77 papers	2,758 citations	186265 28 h-index	182427 51 g-index
77 all docs	77 docs citations	77 times ranked	2481 citing authors

#	Article	IF	Citations
1	Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds. Heart, 2022, 108, 613-618.	2.9	7
2	Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. European Heart Journal, 2022, 43, 3528-3538.	2.2	22
3	MO514: Cardiorenal Outcomes Associated With Oral Anticoagulant Use in Patients With Atrial Fibrillation. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
4	Lessons from 20 years with COXâ€2 inhibitors: Importance of doseâ€“response considerations and fair play in comparative trials. Journal of Internal Medicine, 2022, 292, 557-574.	6.0	42
5	Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f72-f80.	3.0	37
6	Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 3-10.	3.0	15
7	Response to: Kumar N, Ahmed M. Letter to the editor in response to Komen et al. 2021. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e31-e31.	3.0	1
8	Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace, 2021, 23, 1722-1730.	1.7	24
9	Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding. Clinical Pharmacology and Therapeutics, 2020, 107, 287-294.	4.7	10
10	Results of in vitro whole blood coagulation assays using ROTEM and the flow-chamber T-TAS system are affected by hematocrit. Thrombosis Research, 2020, 194, 98-100.	1.7	1
11	Guiding principles for the use of knowledge bases and real-world data in clinical decision support systems: report by an international expert workshop at Karolinska Institutet. Expert Review of Clinical Pharmacology, 2020, 13, 925-934.	3.1	8
12	Lipid levels achieved after a first myocardial infarction and the prediction of recurrent atherosclerotic cardiovascular disease. International Journal of Cardiology, 2019, 296, 1-7.	1.7	15
13	Increased platelet reactivity and plateletâ€“leukocyte aggregation after elective coronary bypass surgery. Platelets, 2019, 30, 975-981.	2.3	12
14	Meal intake increases circulating procoagulant microparticles in patients with type 1 and type 2 diabetes mellitus. Platelets, 2019, 30, 348-355.	2.3	10
15	Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace, 2018, 20, 420-428.	1.7	46
16	Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Nonâ€“Vitamin K Antagonist Oral Anticoagulants. Stroke, 2018, 49, 2122-2128.	2.0	56
17	Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid. Thrombosis Research, 2017, 149, 64-69.	1.7	12
18	Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Nonâ€“Vitamin K Oral Anticoagulants. American Journal of Cardiology, 2017, 120, 1302-1308.	1.6	24

#	Article	IF	Citations
19	Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs. European Journal of Clinical Pharmacology, 2017, 73, 1315-1322.	1.9	14
20	Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. British Journal of Clinical Pharmacology, 2017, 83, 642-652.	2.4	39
21	Meal-induced platelet activation in diabetes mellitus type 1 or type 2 is related to postprandial insulin rather than glucose levels. Thrombosis Research, 2016, 141, 93-97.	1.7	9
22	Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. European Journal of Clinical Pharmacology, 2016, 72, 329-338.	1.9	103
23	Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 944-952.	0.7	23
24	Estimation of dabigatran plasma concentrations in the perioperative setting. Thrombosis and Haemostasis, 2015, 113, 862-869.	3.4	53
25	From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples. Thrombosis Research, 2015, 136, 154-160.	1.7	20
26	Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thrombosis Research, 2015, 135, 852-860.	1.7	26
27	Can the metabolic syndrome be explained by a unifying concept?. Lancet Diabetes and Endocrinology,the, 2015, 3, 96-98.	11.4	1
28	Abstract 13898: Atrial Fibrillation And Persistence With Anticoagulant Treatment. Circulation, 2015, 132, .	1.6	0
29	On the monitoring of dabigatran treatment in â€œreal lifeâ€•patients with atrial fibrillation. Thrombosis Research, 2014, 134, 783-789.	1.7	47
30	Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: Experience from the Stockholm health care system. International Journal of Cardiology, 2013, 170, 208-214.	1.7	69
31	Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. European Journal of Clinical Pharmacology, 2013, 69, 1875-1881.	1.9	98
32	Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thrombosis and Haemostasis, 2013, 110, 543-549.	3.4	92
33	Aspirin resistance testing not ready for "prime time". Heart, 2009, 95, 1220-1222.	2.9	6
34	Î²2-Adrenoceptor desensitization in human alveolar macrophages induced by inhaled terbutaline in vivo is not counteracted by budesonide. Clinical Science, 2001, 100, 451-457.	4.3	3
35	Evaluation of various electrocardiographic criteria for left ventricular hypertrophy in patients with stable angina pectoris: influence of using modified limb electrodes. Clinical Physiology, 2001, 21, 196-207.	0.7	6
36	Platelet-Leukocyte Cross Talk in Whole Blood. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2702-2708.	2.4	191

#	Article	IF	Citations
37	Evidence for Prothrombotic Effects of Exercise and Limited Protection by Aspirin. Circulation, 1999, 100, 1374-1379.	1.6	149
38	Efficient flow cytometric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. Cytometry, 1999, 35, 154-161.	1.8	86
39	Activation of haemostasis by exercise, mental stress and adrenaline: effects on platelet sensitivity to thrombin and thrombin generation. Clinical Science, 1999, 97, 27-35.	4.3	93
40	Acute Effects of Cigarette Smoking on Platelet Function and Plasma Catecholamines in Hypertensive and Normotensive Men. American Journal of Hypertension, 1998, 11, 677-681.	2.0	15
41	Concentration-Dependent Stimulation of Intestinal Phase III of Migrating Motor Complex by Circulating Serotonin in Humans. Clinical Science, 1998, 94, 663-670.	4.3	23
42	No Influence of Simvastatin Treatment on Platelet Function In Vivo in Patients With Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 273-278.	2.4	26
43	Fibrinolytic Variables and Cardiovascular Prognosisin Patients With Stable Angina Pectoris Treated With Verapamil or Metoprolol. Circulation, 1997, 95, 2380-2386.	1.6	78
44	Sympathoadrenal Responses to Bronchoconstriction in Asthma: An Invasive and Kinetic Study of Plasma Catecholamines. Clinical Science, 1995, 88, 439-446.	4.3	14
45	Renal and systemic sympathetic counterregulation in response to vasodilators in renovascular hypertension. Clinical Science, 1993, 84, 41-45.	4.3	1
46	Cardiovascular and Sympatho-Adrenal Responses to Mental Stress in Primary Hypertension. Clinical Science, 1993, 85, 401-409.	4.3	34
47	Impact of Treatment with Acetylsalicylic Acid on the Proaggregatory Effects of Adrenaline in vitro in Patients with Stable Angina Pectoris: Influence of the Anticoagulant. Clinical Science, 1993, 85, 577-583.	4.3	17
48	Is DDD Pacing Superior to VVI,R? A Study on Cardiac Sympathetic Nerve Activity and Myocardial Oxygen Consumption at Rest and During Exercise. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 425-434.	1.2	33
49	Detection of Benzodiazepine Intake in Therapeutic Doses by Immunoanalysis of Urine: Two Techniques Evaluated and Modified for Improved Performance. Clinical Chemistry, 1992, 38, 271-275.	3.2	53
50	Is there a causal relationship of anxiety, stress or cardiovascular reactivity to hypertension?. Stress and Health, 1991, 7, 153-157.	0.5	2
51	Sympathetic Nerve Activity during VVI and DDD Pacing. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 877-877.	1.2	1
52	Plasma Catecholamines as Markers for Sympathoâ€Adrenal Activity in Human Primary Hypertension. Basic and Clinical Pharmacology and Toxicology, 1988, 63, 27-31.	0.0	27
53	Noradrenaline release evoked by a physiological irregular sympathetic discharge pattern is modulated by prejunctional Î±â€•and Î²â€•adrenoceptors in vivo. British Journal of Pharmacology, 1988, 95, 1101-1108.	5.4	17
54	Studies in vivo and in vitro of terbutaline-induced Î²-adrenoceptor desensitization in healthy subjects. Clinical Science, 1987, 72, 47-54.	4.3	49

#	Article	IF	Citations
55	Î²-Adrenoceptor Function in White Blood Cells from Newborn Infants: No Relation to Plasma Catecholamine Levels. Pediatric Research, 1986, 20, 1152-1155.	2.3	19
56	Plasma neuropeptide Yâ€like immunoreactivity and catecholamines during various degrees of sympathetic activation in man. Clinical Physiology, 1986, 6, 561-578.	0.7	192
57	Sympatho-adrenal and cardiovascular reactivity in pregnancy-induced hypertension. I. Responses to isometric exercise and a cold pressor test. BJOG: an International Journal of Obstetrics and Gynaecology, 1985, 92, 722-731.	2.3	61
58	Influence of acetylcholine, peptides, and other vasodilators on endogenous noradrenaline overflow and vasoconstriction in canine blood perfused gracilis muscle. Acta Physiologica Scandinavica, 1985, 124, 457-465.	2.2	19
59	Evidence against a functional role for dopamineâ€4â€sulphate in the kidney. Acta Physiologica Scandinavica, 1985, 125, 739-741.	2.2	5
60	Cardiovascular responses to circulating catecholamines in normal pregnancy and in pregnancyâ€induced hypertension. Clinical Physiology, 1985, 5, 479-493.	0.7	106
61	Theophylline antagonizes cardiovascular responses to dipyridamole in man without affecting increases in plasma adenosine. Acta Physiologica Scandinavica, 1984, 121, 165-171.	2.2	110
62	Further studies on renal nerve stimulation induced release of noradrenaline and dopamine from the canine kidney in situ. Acta Physiologica Scandinavica, 1984, 122, 369-379.	2.2	72
63	Relationship between the overflow of endogenous and radiolabelled noradrenaline from canine blood perfused gracilis muscle. Acta Physiologica Scandinavica, 1984, 122, 571-582.	2.2	61
64	Sympathoâ€adrenal mechanisms and the antihypertensive response to thiazide diuretics. Acta Pharmacologica Et Toxicologica, 1984, 54, 43-45.	0.0	3
65	Comparison of urinary and plasma catecholamine responses to mental stress. Acta Physiologica Scandinavica, 1983, 117, 19-26.	2.2	101
66	A comparison of noradrenaline, HMPG and VMA in plasma as indicators of sympathetic nerve activity in man. Acta Physiologica Scandinavica, 1982, 115, 507-509.	2.2	16
67	Rebound phenomena following withdrawal of longâ€“term Î²â€“adrenoceptor blockade. Acta Medica Scandinavica, 1982, 212, 43-47.	0.0	3
68	Labetalol, a combined Î±â€“ and Î²â€“blocker, in hypertension of pregnancy. Acta Medica Scandinavica, 1982, 212, 143-147.	0.0	7
69	Comparison of the Effects of Different Arachidonic Acid Metabolites on Cyclic Nucleotide Accumulation in Human Peripheral Lymphocytes. Acta Pharmacologica Et Toxicologica, 1982, 51, 336-344.	0.0	3
70	Degeneration release of noradrenaline in skin flaps in rats. Acta Physiologica Scandinavica, 1981, 113, 285-289.	2.2	9
71	Uptake and release of adenosine in isolated rat fat cells. Acta Physiologica Scandinavica, 1979, 105, 257-267.	2.2	12
72	Direct Antilipolytic Effect of Acidosis in Isolated Rat Adipocytes. Acta Physiologica Scandinavica, 1977, 101, 294-301.	2.2	10

#	Article	IF	Citations
73	Inhibition by Acidosis of Adenosine 3â€˜,5â€™â€Cyclic Monophosphate Accumulation and Lipolysis in Isolated Rat Fat Cells¹. Acta Physiologica Scandinavica, 1976, 96, 160-169.	2.2	23
74	Cyclic AMPâ€Dependent and Independent Inhibition of Lipolysis by Adenosine and Decreased pH. Acta Physiologica Scandinavica, 1976, 96, 170-179.	2.2	40
75	Influence of Acidosis on Noradrenalineâ€Induced Vasoconstriction in Adipose Tissue and Skeletal Muscle. Acta Physiologica Scandinavica, 1976, 97, 319-324.	2.2	9
76	Influence of Adipose Tissue Blood Flow on the Lipolytic Response to Circulating Noradrenaline at Normal and Reduced pH. Acta Physiologica Scandinavica, 1976, 98, 74-79.	2.2	12
77	Inhibition of the Lipolytic Response to Nerve Stimulation during Acidosis. Acta Physiologica Scandinavica, 1976, 98, 80-84.	2.2	5